Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Kistemaker, D. J. Slebos, H. Meurs, H. Kerstjens, R. Gosens (Groningen, Netherlands). Anti-inflammatory effects of targeted lung denervation in patients with COPD. Eur Respir J 2014; 44: Suppl. 58, 3333

Member's Comments

No comment yet.

Related content which might interest you: Importance of surface cooling during targeted lung denervation for COPD Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Targeted lung denervation in the healthy sheep model - A potential treatment for COPD Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Effects of inhaled salmeterol/fluticasone on lung function in patients with bronchiectasis Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Effectively targeting small airways using controlled inhalation for peripheral corticosteroid deposition Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 AZD5069: Pharmacological profile of a CXCR2 antagonist in development for the treatment of respiratory disorders Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics Source: International Congress 2014 – Asthma and COPD management Year: 2014 A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Effect of aclidinium/formoterol fixed-dose combinations on respiratory symptoms in COPD patients Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Comparison of three modalities of corticosteroids administration in chronic rhinosinusitis Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Inflammation in COPD patients before and after roflumilast treatment Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Long-acting anticholinergics in the treatment of severe asthma with irreversible airway obstruction Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Improved effects of aerosol-type fluticasone propionate/formoterol combination on residual asthmatic inflammation in distal airways of patients with moderate asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Pharmacological treatment of COPD in the on-sint cohort Source: International Congress 2014 – COPD exacerbations Year: 2014 Anti-inflammatory effects of targeted lung denervation in patients with COPD Source: Eur Respir J 2015; 46: 1489-1492 Year: 2015 Cost-effectiveness of bronchial thermoplasty (BT) treatment relative to no BT treatment option for patients with severe asthma Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Additive effect of targeted lung denervation plus drug in patients with COPD Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 Experience with omalizumab in patients with moderate and severe asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014